Lung function parameters in omalizumab responder patients: An interesting tool?

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Omalizumab, an anti-immunoglobulin E (IgE) antibody, is a treatment for severe allergic asthma.
• Long-term lung function changes and differences between omalizumab responders and nonresponders require further investigation.

Purpose of the Study:

• To compare changes in forced expiratory volume in 1 second (FEV1) between omalizumab responders and nonresponders at 6 months in a real-life setting.

Main Methods:

• A multicenter analysis involving 10 institutions.
• Lung function parameters including FEV1, forced vital capacity (FVC), residual volume (RV), and total lung capacity (TLC) were measured at baseline and 6 months.
• Responder status was determined at 6 months; responders had lung function assessed up to 24 months.

Main Results:

• Responders showed a significant improvement in pre-bronchodilator FEV1 at 6 months (+0.2 L), while nonresponders experienced a decrease (-0.1 L).
• Post-bronchodilator FEV1 improved at 6 months and remained stable for 2 years in responders.
• The proportion of patients with an FEV1/FVC ratio <0.7 decreased significantly over 24 months in responders.

Conclusions:

• Omalizumab treatment leads to a significant improvement in FEV1 at 6 months, which is sustained for 2 years in responders.
• Residual volume (RV) and the RV/TLC ratio demonstrated improvements at 6 months post-omalizumab initiation.